Lyell Immunopharma, Inc. (LYEL): Price and Financial Metrics

Lyell Immunopharma, Inc. (LYEL): $1.12

0.16 (+16.63%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

C

Add LYEL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#183 of 328

in industry

LYEL Price/Volume Stats

Current price $1.12 52-week high $3.26
Prev. close $0.96 52-week low $0.85
Day low $0.94 Volume 1,968,400
Day high $1.18 Avg. volume 989,012
50-day MA $1.25 Dividend yield N/A
200-day MA $1.88 Market Cap 286.72M

LYEL Stock Price Chart Interactive Chart >


Lyell Immunopharma, Inc. (LYEL) Company Bio


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


LYEL Latest News Stream


Event/Time News Detail
Loading, please wait...

LYEL Latest Social Stream


Loading social stream, please wait...

View Full LYEL Social Stream

LYEL Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year N/A
5-year N/A
YTD N/A
2023 N/A
2022 N/A
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!